

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

DR. REDDY'S LABORATORIES S.A. and DR. REDDY'S
LABORATORIES, INC.,
Petitioners,

v.

INDIVIOR UK LIMITED,
Patent Owner.

IPR2019-00329
Patent 9,687,454 B2

PETITIONERS' NOTICE OF CROSS-APPEAL

via PTAB E2E
Patent Trial and Appeal Board

via Hand Carry
Director of the United States Patent and Trademark Office
c/o Office of the General Counsel, 10B20
Madison Building East
600 Dulany Street
Alexandria, VA 22314

via CM/ECF
United States Court of Appeals for the Federal Circuit

INTRODUCTION

On July 24, 2020, Indivior UK Limited (“Indivior”) filed a notice of appeal of the Patent Trial and Appeal Board’s Final Written Decision entered on June 2, 2020 (Paper 49) (the “Final Written Decision”), in the above-captioned *inter partes* review of United States Patent No. 9,687,454 B2. Petitioners Dr. Reddy’s Laboratories S.A. and Dr. Reddy’s Laboratories, Inc. (collectively, “DRL”) file this notice of cross-appeal from the Final Written Decision. This notice of cross-appeal is timely filed within 14 days of Indivior’s Notice of Appeal. Fed. R. App. P. 4(a)(3); 37 C.F.R. § 90.3(a)(1).

DRL’S CROSS-APPEAL

Please take notice that, pursuant to 35 U.S.C. §§ 141(c), 142, 319; 37 C.F.R. §§ 90.2(a)(1), 90.3(a); and Federal Circuit Rule 15, DRL hereby cross-appeals to the United States Court of Appeals for the Federal Circuit from the Final Written Decision and from all underlying orders, decisions, rulings and opinions.

DRL’S ISSUES ON CROSS-APPEAL

In accordance with 37 C.F.R. § 90.2(a)(3)(ii), DRL’s issues on cross-appeal include at least: (i) whether the Board erred in holding that DRL had failed to show by a preponderance of the evidence that Claim 8 of U.S. Patent No. 9,687,454 B2 is unpatentable; and (ii) any finding or determination supporting or related to this issue and all other issues decided adversely to DRL in any order,

decision, ruling, phone conference decision, and/or opinion.

Simultaneously with this submission, DRL is filing (i) a true and correct copy of this Notice of Appeal with the Director of the United States Patent and Trademark Office and (ii) a true and correct copy of the same, along with the required docketing fee, with the Clerk of the United States Court of Appeals for the Federal Circuit as set forth in the accompanying Certificate of Filing.

Dated: August 7, 2020

Respectfully submitted,

By: /Ira J. Levy/

Registration No. 35,587
Goodwin Procter LLP
The New York Times Building
620 Eighth Avenue
New York, NY 10018-1405
T: 212-459-7456
F: 212-355-3333
ILevy@goodwinlaw.com

Case IPR2018-01422
Patent No. 9,340,614

CERTIFICATE OF FILING

I certify that, in addition to being electronically filed through PTAB E2E, a copy of **PETITIONERS' NOTICE OF CROSS-APPEAL** is being filed by hand with the Director on August 7, 2020 at the following address:

Director of the United States Patent and Trademark Office
c/o Office of the General Counsel, 10B20
Madison Building East
600 Dulany Street
Alexandria, VA 22314

I also certify that on this 7th day of August, 2020, a copy of **PETITIONERS' NOTICE OF CROSS-APPEAL** and the filing fee is being filed via CM/ECF with the Clerk's Office of the United States Court of Appeals for the Federal Circuit.

Dated: August 7, 2020

By: /Ira J. Levy/

Registration No. 35,587
Goodwin Procter LLP
The New York Times Building
620 Eighth Avenue
New York, NY 10018-1405
T: 212-459-7456
F: 212-355-3333
ILevy@goodwinlaw.com

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. § 42.6(e), I certify that on this 7th day of August, 2020, I caused to have served a copy of **PETITIONERS' NOTICE OF CROSS-APPEAL** electronically via email on the following:

dgarr@cov.com

pchen@cov.com

IndiviorSBX@cov.com

Dated: August 7, 2020

By: /Ira J. Levy/

Registration No. 35,587
Goodwin Procter LLP
The New York Times Building
620 Eighth Avenue
New York, NY 10018-1405
T: 212-459-7456
F: 212-355-3333
ILevy@goodwinlaw.com